1-3 of 3
Rauf Haznedar
Close
Sort by
Journal Articles

Kiler Immunoglobulin Receptor(KIR) Ligands Are Associated with At Least Partial (HLA A*03, B*44) or Poorer (HLA B*51, C*04) Response to Thalidomide Among Patients with Multiple Myeloma Treated in Two Turkish Centers

Elif Suyani, MD, Sule Mine Bakanay, MD, Klara Dalva, MD, Ezgi Cakmak, MSc, Rauf Haznedar, MD, Gulsan Sucak, MD, Meral Beksac, MD
Journal: Blood
Blood (2012) 120 (21): 4904.
https://doi.org/10.1182/blood.V120.21.4904.4904
Published: 2012
Journal Articles

A new target for myeloma therapy

Rauf Haznedar
Journal: Blood
Blood (2012) 119 (6): 1325–1326.
https://doi.org/10.1182/blood-2011-12-394486
Published: 2012
Journal Articles

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

Clinical Trials & Observations
Peter M. Fayers, Antonio Palumbo, Cyrille Hulin, Anders Waage, Pierre Wijermans, Meral Beksaç, Sara Bringhen, Jean-Yves Mary, Peter Gimsing, Fabian Termorshuizen, Rauf Haznedar, Tommaso Caravita, Philippe Moreau, Ingemar Turesson, Pellegrino Musto, Lotfi Benboubker, Martijn Schaafsma, Pieter Sonneveld, Thierry Facon, on behalf of the Nordic Myeloma Study Group, Italian Multiple Myeloma Network, Turkish Myeloma Study Group, Hemato-Oncologie voor Volwassenen Nederland, Intergroupe Francophone du Myélome, and European Myeloma Network
Journal: Blood
Blood (2011) 118 (5): 1239–1247.
https://doi.org/10.1182/blood-2011-03-341669
Published: 2011